BiotechTube
LiberoThera

LiberoThera

Tokyo, Japan· Est.

Japanese biotech developing antibody therapeutics using proprietary cell-free membrane protein and non-canonical amino acid technologies.

liberothera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Estimated funding: $10M

AI Company Overview

Japanese biotech developing antibody therapeutics using proprietary cell-free membrane protein and non-canonical amino acid technologies.

OncologyImmunology

Technology Platform

Proprietary cell-free membrane protein preparation system combined with non-canonical amino acid incorporation technology to enable antibody discovery against challenging membrane protein targets like GPCRs.

Opportunities

Large market potential for antibodies against GPCRs and other membrane proteins in oncology and immunology; potential for platform licensing and additional partnerships with larger biopharma companies.

Risk Factors

Early-stage preclinical pipeline with unproven clinical efficacy; competition from numerous companies targeting similar pathways; reliance on future funding to advance programs to clinical trials.

Competitive Landscape

Competes with other companies developing antibodies against GPCRs and membrane proteins, but differentiates through proprietary cell-free protein production and non-canonical amino acid technologies that may enable access to previously undruggable targets.

More companies in Japan →